摘要急性髓系白血病是由于造血多能干细胞发生不同基因突变而导致的一组异质性克隆性疾病.该文综述了儿童急性髓系白血病分型、危险度分级、正在进行中的三期临床试验治疗结果和微小残留病管理.此外,还简述了新型化疗药物如吉姆单抗奥佐米星、柔红霉素脂质体、氯法拉滨、克拉屈滨和伊马替尼以及异基因造血干细胞移植在儿童急性髓系白血病中的应用.

abstractsAcute mveloid leukemia(AML) is a heterogeneous group of leukemias that arise from clonal transformation of hematopoietic precursors.This review summarizes classification of pediatric AML,more precise risk-group stratification,ongoing phase Ⅲ studies and minimal residual diseasse monitoring.In addition,we discuss the opportunities for innovative chemotherapy drugs in refractory AML and relapsed AML,such as gemtuzumab ozogamicin,liposomal daunorubicin,clofarabine,cladribine and lmatinib.Finally,the roles of allogeneic hematopoietic stem cell transplantation in pediatric AML are also discussed.